Abstract 2572
Background
Clinical trials have failed to show benefit from adding anti-EGFR antibodies to chemotherapy in the systemic treatment of biliary tract cancer with respect to progression free and overall survival, but a trend towards higher response rate. In colorectal cancer, effect of anti-EGFR therapy is restricted to patients with RAS and BRAF wild-type tumors. Mutation analysis of circulating DNA may be a clinically applicable method for serial analyses. The purpose of this early cancer biomarker study was to evaluate the feasibility of extended RAS and BRAF mutation analysis of cell free DNA in blood derived from patients with metastatic biliary tract cancer.
Methods
Patients with KRAS exon 2 codons 12/13 wild type metastatic biliary tract cancer and available blood samples were included. DNA was isolated from 4 ml plasma, pre-amplified and analyzed using Droplet Digital PCR. Adequate positive and negative controls were included. The extended RAS and BRAF analysis covered a total of 27 mutations in KRAS exons 3/4, NRAS exon 2/3 and BRAF V600E.
Results
A total of 52 patients were included. In 12 patients (23.1%), a mutation was found; BRAF n = 4, KRAS n = 4 and NRAS n = 4. Except for one patient with a NRAS mutation in plasma and wild-type in tumor, tumor biopsies harbored an identical mutation.
Conclusions
Extended RAS and BRAF mutation analysis in cell free DNA from blood derived from patients with metastatic biliary tract cancer was feasible. The fraction of mutations was 23.1% and equally distributed in KRAS, NRAS and BRAF. The high frequency of mutations beyond KRAS exon 2 may explain the lacking effect of EGFR inhibition in previous studies and justify extended mutation analysis.
Clinical trial identification
NA
Legal entity responsible for the study
Lars Henrik Jensen
Funding
Lillebaelt Hospital
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract